- Conditions
- Insulin Sensitivity, Obesity
- Interventions
- Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
- Other
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Galveston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 94
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelofibrosis
- Interventions
- Imetelstat sodium, Ruxolitinib
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Coral Gables, Florida + 3 more
- Conditions
- Plaque Psoriasis
- Interventions
- Zasocitinib, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 11
- States / cities
- Chula Vista, California • Fountain Valley, California • Hialeah, Florida + 8 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- ABT-869, paclitaxel, Placebo for ABT-869
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- San Francisco, California • Harvey, Illinois
- Conditions
- Obesity and Overweight
- Interventions
- MET233, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Breast Cancer, Cardiotoxicity
- Interventions
- antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
- Other · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- HIV-1
- Interventions
- F/TAF, 3rd ARV agent, Boosted PIs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more
- Conditions
- Obesity
- Interventions
- JITAI Enhanced Education Intervention Option, JITAI Self-Efficacy Intervention Option, JITAI Motivation Intervention Option, JITAI Self-Regulation Intervention Option, JITAI Generic Risk Alert Intervention Option (Active Comparator), Online Behavioral Obesity Treatment, JITAI No Treatment Intervention Option
- Behavioral
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Solid Tumors
- Interventions
- mRNA-4157, Pembrolizumab, SoC Treatment
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
- Conditions
- High Grade Serous Carcinoma
- Interventions
- Olaparib Pill, AZD6738
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Mantle Cell Lymphoma, Refractory Lymphoma
- Interventions
- Acalabrutinib, Venetoclax, Obinutuzumab
- Drug
- Lead sponsor
- Austin I Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Non-small Cell Lung Cancer(NSCLC)
- Interventions
- AT13387, Crizotinib
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 38
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- Mild Cognitive Impairment, Insomnia
- Interventions
- Multicomponent Behavioral Sleep Intervention for Insomnia, Active Control
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- ZB716, Palbociclib
- Drug
- Lead sponsor
- EnhancedBio USA Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY3337641, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 15
- States / cities
- Palm Desert, California • Palo Alto, California • Denver, Colorado + 12 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Matching placebo, Cenerimod
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Anniston, Alabama • Clearwater, Florida
- Conditions
- Hepatitis B
- Interventions
- JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Weight Management
- Interventions
- GS-4571, Placebo, Omeprazole
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Substance Use Disorders
- Interventions
- SBIRT, SBIRT+RMC-PC
- Behavioral
- Lead sponsor
- Chestnut Health Systems
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Lansing, Illinois • Oak Park, Illinois
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- EVG, Background regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 4 Weeks to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
- Conditions
- Arthritis, Rheumatoid
- Interventions
- PRTX-100
- Drug
- Lead sponsor
- Protalex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Coeur d'Alene, Idaho
- Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
- Conditions
- Angelman Syndrome
- Interventions
- ION582
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 6
- States / cities
- San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more